FactSet Research Systems
FDS is a leading provider of financial data, analytics, and software solutions primarily serving the investment and finance industry. As of 2025, it supports over 218,000 users across more than 8,200 client institutions worldwide, including buy-side and sell-side firms, investment managers, hedge funds, banks, wealth managers, asset owners, private equity firms, and corporate users. Its clients span industries such as financial services (19% of users), higher education (11%), and investment management (7%), with a strong focus on large organizations (38% of clients have revenue >$1B).
Technical Analysis:
The price is currently touching the top of my "crash" historical simple moving average bands (green lines). This area is often reserved for share accumulation and can signal a bottom. The price, however, may extend to the bottom of "crash" bands which is currently near $265.00. These bands don't always signal a bottom - there is a still a "major crash" zone - but the company's niche clientele and earnings/revenue growth into 2029 may signal a buy opportunity.
Earnings and Revenue Growth
Health
Insiders
Action
Due to the expected earnings and revenue growth into 2029, great overall financial health, niche market served, and technical analysis signals,
FDS is in a personal "buy zone" at $284.10. Additional opportunities for entry may exist near $265 and a bit lower in the near-term. However, if estimates are correct and continued growth is in the future of
FDS , the long-term outlook may be quite positive for investors. Time will tell.
Targets in 2028
Technical Analysis:
The price is currently touching the top of my "crash" historical simple moving average bands (green lines). This area is often reserved for share accumulation and can signal a bottom. The price, however, may extend to the bottom of "crash" bands which is currently near $265.00. These bands don't always signal a bottom - there is a still a "major crash" zone - but the company's niche clientele and earnings/revenue growth into 2029 may signal a buy opportunity.
Earnings and Revenue Growth
- EPS growth between 2025 ($16.98) and 2029 ($22.30): 31.3%
- Revenue growth between 2025 ($2.32 billion) and 2029 ($2.86 billion): 23.3%
- https://www.tradingview.com/symbols/NYSE-FDS/financials-earnings/?earnings-period=FY&revenues-period=FY
Health
- Debt-to-Equity: 0.63x (good)
- Altman's Z-Score/Bankruptcy Risk: 6.6 (great, very low risk)
Insiders
- Warnings: selling outweighs buying, but an insider two days ago purchased $100k near $296.
- http://openinsider.com/FDS
Action
Due to the expected earnings and revenue growth into 2029, great overall financial health, niche market served, and technical analysis signals,
Targets in 2028
- $320 (+12.6%)
- $350 (+23.2%)
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.